Recce Pharmaceuticals teams with leading Indonesian biomed company for anti-infective push
Recce Pharmaceuticals to expand diabetes foot infection trial as results prove strong
Recce secures Australia’s largest-ever $11m Advanced Overseas R&D Finding
Recce Pharmaceutical speeds up R327 dose as it works to bring new anti-infective to market
Recce Pharmaceuticals accelerates R327 trial for UTI patients with faster infusion rate approval
Busiest quarter for Recce Pharmaceuticals: Cashed up for next phases of drug development
RCE'S RAISE TO PROGRESS ADVANCED ANTI-INFECTIVE
Recce Pharmaceuticals (ASX:RCE) receives green light for higher dose in rapid infusion phase I/II UTI trial
Recce Pharmaceuticals (ASX:RCE) doses phase I/II patients in R327 diabetic foot infection trial
Recce Pharmaceuticals’ US leaders Down Under to drive R327 clinical trials
CEO buys another $300,000 stake in Recce Pharmaceuticals
Recce Pharmaceuticals selected by West Australian Government to attend BIO Korea 2023
Recce’s (ASX:RCE) works to confirm efficacy of first breakthrough antibiotic in two decades
Recce Pharmacuticals (ASX:RCE) adds to its patent portfolio
Recce Pharma (ASX:RCE) Selects CMAX for Phase I/II UTI Clinical Trials
Recce Pharma (ASX:RCE) selects CMAX for phase I/II UTI clinical trial
RCE outlines strong pipeline of pre-clinical and clinical programs
Recce Pharmaceuticals (ASX:RCE) reports R237 drug “significantly” reduces SARS-CoV-2 in hamsters
Recce Pharmaceuticals (ASX:RCE) poised to revolutionise the treatment of deadly infections – is R327 the muti-billion dollar answer to super bugs?
Recce Pharmaceuticals (ASX:RCE) expands and accelerates clinical programs
Recce Pharmaceuticals (ASX:RCE) successfully doses seventh trial cohort with R327
Recce Pharmaceuticals (ASX:RCE) makes quarterly progress on R327
Recce Pharmaceuticals (ASX:RCE) reports positive safety data latest cohort in R327 trial
Recce Pharmaceuticals’ (ASX:RCE) clinical trial returns positive safety profile
(ASX:RCE): A multi-billion-dollar sepsis solution?
RCE REPORTS POSITIVE RESULTS FROM R327 TRIALS
(ASX:RCE) clinical trial progress points to safety of R327
Recce Pharmaceuticals (ASX:RCE, FSE:R9Q) shares spike following results from the team’s Clinical Trial for the Treatment of Burn Wound Infections. James Graham, Recce CEO, discusses the exciting progress and what this means for shareholders
(ASX:RCE) receives ethics approval to begin R327 trial
Recce Pharmaceuticals (ASX:RCE) granted US patent
Recce Pharmaceuticals (ASX:RCE) begins clinical trials at Fiona Stanley Burns Unit.
Recce Pharmaceutics (ASX:RCE) begins patient dosing for clinical trial
Recce Pharmaceuticals RCE – their patented treatment taking on COVID, Sepsis & Burns
Recce Pharmaceuticals’ (ASX:RCE) anti-infective treatment effective against antibiotic-resistant pathogens
Interview with James Graham, Executive Director - Recee Pharmaceuticals
